Resultats globals: 3 registres trobats en 0.01 segons.
Articles, 3 registres trobats
Articles 3 registres trobats  
1.
1 p, 118.3 KB Correction to : Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey / Lebwohl, Mark (Icahn School of Medicine at Mount Sinai) ; Langley, Richard G. (Dalhousie University) ; Paul, Carle (Paul Sabatier University) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Reich, Kristian (University Medical Center Hamburg-Eppendorfi) ; van de Kerkhof, Peter (Radboud University Medical Center) ; Wu, Hsiuan-Lin (Amgen Inc) ; Richter, Sven (Amgen Inc) ; Jardon, Shauna (Amgen Inc) ; Gisondi, Paolo (University Hospital of Verona (Itàlia)) ; Universitat Autònoma de Barcelona
2022 - 10.1007/s13555-021-00656-z
Dermatology and Therapy, Vol. 12 (january 2022) , p. 79  
2.
16 p, 894.7 KB Evolution of Patient Perceptions of Psoriatic Disease : Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey / Lebwohl, Mark (Icahn School of Medicine at Mount Sinai) ; Langley, Richard G. (Dalhousie University) ; Paul, Carle (Paul Sabatier University) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Reich, Kristian (University Medical Center Hamburg-Eppendorf) ; van de Kerkhof, Peter (Radboud University Medical Center) ; Wu, Hsiuan-Lin (Amgen Inc) ; Richter, Sven (Amgen Inc) ; Jardon, Shauna (Amgen Inc) ; Gisondi, Paolo (University Hospital of Verona (Itàlia)) ; Universitat Autònoma de Barcelona
Since the 2012 Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey, several systemic treatments for psoriasis (PsO) and/or psoriatic arthritis (PsA) have been approved. The population-based UPLIFT survey was conducted to understand how perceptions of treatment-related outcomes have evolved, particularly for patients with mild to moderate PsO and/or PsA and their dermatologists. [...]
2021 - 10.1007/s13555-021-00635-4
Dermatology and Therapy, october 2021, p. 1-16  
3.
18 p, 504.6 KB Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis : Results from Greater Than 17,000 Patient-Years of Exposure / Armstrong, April (Keck School of Medicine of the University of Southern California. Department of Clinical Research) ; Paul, Carle (Paul Sabatier University. Dermatology Department, Toulouse University Hospital (CHU)) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Boehncke, Wolf Henning (University of Geneva. Department of Pathology and Immunology) ; Freeman, Michael (The Skin Centre, Benowa, QLD Australia) ; Torii, Hideshi (Tokyo Yamate Medical Center. Division of Dermatology) ; Papp, Kim (K Papp Clinical Research and Probity Medical Research) ; Griffiths, Christopher E. M. (NIHR Manchester Biomedical Research Centre. Dermatology Centre, Salford Royal Hospital, University of Manchester) ; Blauvelt, Andrew (Oregon Medical Research Center) ; Reich, Kristian (Skinflammation® Center, Hamburg, Germany) ; Gooderham, Melinda (Centre for Dermatology and Probity Medical Research, Peterborough, ON Canada) ; Terui, Tadashi (Nihon University School of Medicine. Department of Dermatology) ; Renda, Lisa (Eli Lilly and Company) ; Agada, Noah (Eli Lilly and Company) ; Xu, Wen (Eli Lilly and Company) ; Gallo, Gaia (Eli Lilly and Company) ; Lebwohl, Mark G. (Icahn School of Medicine at Mount Sinai. Department of Dermatology) ; Universitat Autònoma de Barcelona
Long-term safety data are critical for evaluating therapies for psoriasis. Ixekizumab has demonstrated efficacy and is well tolerated for the treatment of moderate-to-severe plaque psoriasis. We examined the safety and tolerability of up to 5 years of ixekizumab therapy in patients with psoriasis. [...]
2019 - 10.1007/s13555-019-00340-3
Dermatology and Therapy, Vol. 10 (november 2019) , p. 133-150  

Vegeu també: autors amb noms similars
2 Reich, K.
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.